Medicalgorithmics, a global medtech company, listed on the Warsaw Stock Exchange, is proud to announce strategic changes within its leadership team to further its transition from a heart monitoring device manufacturer to a dynamic AI-driven software platform developer and data analytics service provider. These changes include the promotion of James Landis to the position of Executive Vice President of Global Sales and Marketing, and the appointment of Jaroslaw Jerzakowski as Chief Operating Officer.
In his new role as Executive Vice President of Global Sales and Marketing, James Landis will play a pivotal role in accelerating the company’s growth trajectory. Since joining Medicalgorithmics in March 2023, Mr. Landis originated several collaborations and integrations with leading heart monitoring hardware and IDTF customers. He brings a wealth of experience in building high-performance commercial teams within rapidly evolving sectors, particularly in biometrics monitoring. In his expanded capacity, Mr. Landis will oversee the global sales and marketing resources, capitalizing on established teams in EMEA and APAC regions.
Complementing this strategic move, Jaroslaw Jerzakowski assumes the role of Chief Operating Officer to expand and enhance Company operations. Mr. Jerzakowski, a seasoned professional within Medicalgorithmics, possesses profound industry knowledge and a deep understanding of the intricate commercial, regulatory, and operational nuances associated with integrating new customers into the PC Client platform. These integrations empower Medicalgorithmics’ customers to differentiate their product and service offerings by harnessing the clinical insights and operational efficiencies enabled by AI-driven data analytics. Additionally, Mr. Jerzakowski will steer the expansion of the service and logistics business lines, providing value-added contributions to companies seeking growth across the EMEA and APAC regions.
Additionally, responding to the robust growth of Medicalgorithmics, the supervisory board of the Company has appointed one of its members, David Cash, to oversee the sales area.
Kris Siemionow MD, Chairman of Biofund, the major shareholder of Medicalgorithmics, remarked, “Our decision to bolster the leadership team stems from the remarkable demand for the digital platform since its unbundling from the hardware line after the 2022 BioFund investment. With these strategic leadership changes, we are poised not only to expedite sales growth under James’ leadership, but also to position Jarek to seamlessly integrate these new customers on our software platform while further capitalizing on untapped opportunities within our service and logistical support businesses. We are extremely pleased with our progress thus far and remain highly optimistic about our growth prospects in 2024.”
These leadership changes represent a pivotal moment for Medicalgorithmics, affirming its commitment to innovation, customer integration, and global expansion. The company’s mission to advance healthcare through cutting-edge technology and data-driven insights is underpinned by these strategic appointments.
Medicalgorithmics is a global medtech company, specializing in AI-enhanced, non-invasive cardiac diagnostic solutions. Its broad portfolio of products augments patient monitoring, enabling prompt ailment detection, accurate diagnosis, and meticulous health oversight. Such innovations provide healthcare professionals with unparalleled insights, optimize workflows, and substantially curtail the need for manual data assessments by technicians.